Endometriosis (EM) is a kind of estrogen-dependent disease in reproductive-age women. Ovarian EM is the most common type. Although EM is a benign disease, it shares many similar features with cancers. Programmed cell death 4 (PDCD4), a newly identified tumor suppressor, plays an important role in inhibiting tumorigenesis and tumor progression at the transcriptional and translational levels. To explore the roles of PDCD4 in EM, we detected the expression of PDCD4 in control endometrium and eutopic/ectopic endometrium of ovarian EM patients, and analyzed the effects of PDCD4 on the biological behaviors of endometrial cell lines and primary endometrial cells. The results demonstrated that PDCD4 was downregulated in eutopic and ectopic endometrium of EM patients compared with control endometrium. PDCD4 effectively inhibited the proliferation and colony-forming ability of endometrial cells maybe by inhibiting cell autophagy. In addition, PDCD4 also suppressed the migration and invasion ability of endometrial cells, the mechanism may be related to NF-κB/MMP2/MMP9 signal pathway. Taken together, these results suggest that PDCD4 could be involved in the pathogenesis of EM, and provide a novel approach to target the aberrant PDCD4 expression in EM.
Introduction
Endometriosis (EM) is a common gynecological disorder affecting 10%-15% women in reproductive age [1] . It is defined as the presence of uterine endometrial glands and stroma outside the uterine cavity, including pelvis, upper abdomen, lung, and even central nervous system [2] . The predominant site of EM is the ovary (96.4%), followed by the soft tissue (2.8%), gastrointestinal tract (0.3%), and urinary tract (0.2%) [3] . Endometriosis results in chronic pelvic pain, nearly 50% women with EM have chronic pelvic pain, especially during menstruation. In addition, EM is also the most important cause of infertility, 30%-50% women with EM have infertility [4] .
The main theories for the formation of ectopic endometrium are retrograde menstruation and implantation. The retrograde menstruation is a physiologic process that takes place almost in all menstruation cycles of reproductive-age women; however, the morbidity of EM is only 10%-15%. In addition, EM is estrogen-dependent disease [5] . It is reported that estrogen is necessary but not sufficient to sustain EM because estrogen promotes implantation of endometrial tissue to ectopic locations but failure of these ectopic lesions to grow and sustain even in high estrogenic environment [6] . Now, more and more studies show that the primary defect in EM is located in the eutopic endometrium [7] . It has been known that some genes are expressed differentially in eutopic endometrium of EM patients compared with control endometrium [8, 9] . However, the cellular and molecular characteristics of eutopic endometrium in patients with EM have not been fully elucidated.
Programmed cell death 4 (PDCD4) was initially identified as a protein induced by apoptotic stimuli [10] . Recent studies show that PDCD4 is a novel tumor suppressor which plays important roles by inhibiting protein translation or activator protein-1 (AP-1) transactivation and transformation, as well as nuclear factor-κB (NF-κB)-dependent transcription [11] [12] [13] . PDCD4 mRNA and protein are significantly downregulated in various human cancers such as hepatocellular carcinoma, glioma, breast carcinoma, gastric cancer, and ovarian cancer [14] [15] [16] [17] . PDCD4 overexpression induces tumor cell apoptosis or cell cycle arrest, increases sensitivity of tumor cells to antitumor drugs, and inhibits tumor cell migration and invasion, as well as angiogenesis [18] . Besides, PDCD4 is also an inflammatory factor involved in obesity, adipose tissue inflammation, atherosclerosis, and lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute injury [19, 20] .
Although EM is a kind of benign disease, previous reports suggest that it shares many similar features with cancers, such as abnormal cell migration, invasion, and unrestrained growth [21] . Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be also related to the pathogenesis of pelvic EM [22] . About 10%-15% of EM cases are found to be more aggressive and tend to invade deep into the affected tissues and organs, producing more severe clinical symptoms [23] , and deep infiltrating EM usually does not respond well to hormonal suppressive therapy. Based on the critical functions of PDCD4 in malignant tumor, we could clarify the possible roles of PDCD4 in EM and develop new and effective methods for diagnosis and treatment of EM.
Many signaling pathways take part in the pathogenesis of EM, including NF-κB signaling pathway. This pathway is also involved in cell metastasis, adhesion, and migration because it modulates the expression of downstream targets such as matrix metalloproteinases (MMPs) [24] . In the present study, we detected the expression of PDCD4 in endometrium of women with or without EM and analyzed the effect and possible mechanism of PDCD4 on the biological behaviors of endometrial cells.
Materials and methods

Patients and clinical samples
Eutopic and ectopic endometrium tissues were obtained from 26 patients with ovarian EM in Department of Obstetrics and Gynecology, Jinan Central Hospital affiliated Shandong University between January 2015 and January 2016. All the women had visual or biopsy-proven EM. The control endometrium was collected from 35 women, who were suffered from laparoscopic surgery and confirmed absence of visible EM by histological detection. None of these patients had received any hormones or antibiotics treatment in the last 6 months prior to the surgery. All the samples were acquired in the proliferative or secretory phase based on the menstrual cycle and histological evaluation. No statistically significant differences in age were found between EM patients and normal controls. Written informed consent was obtained from all the participants, and the study was approved by the Ethics Committee of the Medical Faculty, Shandong University.
Antibodies
Rabbit monoclonal antibodies specific for PDCD4, p-P65, and P65 were purchased from Cell Signaling Technology (Boston, MA, USA). Rabbit monoclonal antibodies specific for MMP2 and MMP9 were purchased from Abcam (Cambridge, UK). Rabbit monoclonal antibody specific for autophagy-related marker LC3B was purchased from Sigma (Saint Louis, Missouri, USA) and β-actin antibody was purchased from ZSJQB Company (Beijing, China).
RNA extraction and quantitative real-time polymerase chain reaction
Total RNA from eutopic endometrium and control endometrium was extracted using Trizol Reagent (TIANGEN, Beijing, China), and then reversely transcribed into complementary DNA (cDNA) with a FastQuant RT Kit (With gDNase) (TIANGEN, Beijing, China). Quantitative real-time polymerase chain reaction (qRT-PCR) for PDCD4 and GAPDH was respectively performed in 20 μL volume containing 0.2 μL of cDNA, 10 μL of UltraSYBR Mixture (CWBIO, China), and 1 μL of each primer. The sequences of the sense and antisense primers were as follows: PDCD4: 5 -ACA GGT GTA TGA  TGT GGA GGA-3 and 5 -TTC TCA AAT GCC CTT TCA TCC  AA-3 ; GAPDH: 5 -AAC GGA TTT GGT CGT ATT GGG-3 and  5 -CCT GGA AGA TGG TGA TGG GAT-3 . The PCR protocol was as follows: pre-denaturation at 95
• C for 10 min, followed by 39 cycles of amplification at 95
• C for 15 s, 60
• C for 1 min, 65
• C for 5 s.
GAPDH was served as an internal control to normalize difference in loaded cDNA. Each sample was examined in triplicate. Data were analyzed using the 2 − Ct method.
Western blot assay
The eutopic endometrium and control endometrium were lysed by radioimmunoprecipitation assay buffer containing 1% phenylmethanesulfonyl fluoride and 0.5% phosphatase inhibitor (PI). PDCD4 mRNA levels in the eutopic endometrium of endometriosis patients were lower than those in control endometrium detected by quantitative real-time PCR (qRT-PCR) (P < 0.05). Data were normalized to GAPDH. (B) PDCD4 protein levels in the eutopic endometrium of endometriosis were lower than those in control endometrium detected by western blotting. (C) The immunostaining of PDCD4 in eutopic and ectopic endometrium of endometriosis patients and control endometrium was detected by immunohistochemistry (×200 magnification). (I) The proliferative phase of control endometrium; (II) the secretory phase of control endometrium; (III) the proliferative phase of eutopic endometrium from patients with endometriosis; (IV) the secretory phase of eutopic endometrium from patients with endometriosis; (V) the ectopic endometrium of endometriosis patients. (D) The expression of PDCD4 protein in the eutopic and ectopic endometrium of endometriosis patients was significantly lower than that in control endometrium (P < 0.05). (E) In control endometrium, the staining index of PDCD4 in the proliferative phase was significantly higher than that in the secretory phase (P < 0.05). Compared with the proliferative phase of control endometrium, PDCD4 expression is significantly decreased in the proliferative phase of eutopic endometrium (P < 0.05) or ectopic endometrium (P < 0.01). * P < 0.05; * * P < 0.01.
The bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL, USA) was used to measure the protein concentrations. Each sample (40 μg) was separated by 10% SDS-polyacrylamide gel, and then transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). β-actin was used as a loading control. The membranes were blocked with 5% bovine serum albumin and then incubated with 1:1000 dilution of specific primary antibodies at 4 • C overnight. After being washed with 0.1%
Tween in Tris-buffered saline, the membranes were incubated with 1:2000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson Immuno Research, West Grove, PA, USA) for 1 h at room temperature. The signal was detected by the enhanced chemiluminescence kit (Thermo Scientific, MA, USA).
Immunohistochemistry
The tissue slides from eutopic or ectopic endometrium and control endometrium were deparaffinized by xylene and hydrated with graded ethanol. After antigen microwave retrieval and endogenous peroxide blocking, the slides were blocked by 10% goat serum for 15 min at 37
• C, and then incubated overnight at 4 • C with 1:100 dilution of primary antibody against PDCD4. Next, the slides were incubated with HRP-conjugated goat anti-rabbit IgG (Gene Tech, Shanghai, China) for 30 min at 37 • C and visualized using diaminobenzamidine (DAB) kit (Gene Tech). The nuclei were counterstained with hematoxylin. For negative controls, primary antibody was replaced with PBS. The expression of PDCD4 was evaluated based on the staining intensity and positive expression area. The intensity of staining was characterized as follows: --(score 0), +(score 1), ++(score 2), and +++(score 3). The positive expression area was graded as follows: --(<1%, score 0), +(1%-33%, score 1), ++(34%-66%, score 2), and +++(67%-100%, score 3). The sum of intensity and percentage scores was used as the final PDCD4 staining score. The expression of PDCD4 was defined as follows: no expression (total score 0); weak expression (total score 1 and 2); moderate expression (total score 3 and 4); strong expression (total score 5 and 6). All the immunohistochemistry (IHC) slides were observed by two independent pathologists who were blinded to the patients' clinical data.
Cell culture and reagents
Human endometrial cell line HEC-1-A was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in McCoy's 5A medium (Gibco, CA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco), and Penicillin/Streptomycin (HyClone, Logan, UT, USA). Ishikawa cells were provided by QiLu Hospital Affiliated to Shandong University and cultured in Dulbecco's modified Eagle medium (DMEM; HyClone),supplemented with 10% FBS and Penicillin/Streptomycin.
The isolation of glandular epithelial cells and stromal cells derived from control endometrium
Endometrial glandular epithelial cells and stromal cells were isolated from secretory phase of control endometrium as previously described [25] with slight modification, and cultured in DMEM/F12 (1:1) (HyClone Corporation, Beijing, China) supplemented with 10% FBS, L-Glutamine (2 mM; Sigma-Aldrich), and 100 U/ml of Penicillin and Streptomycin at 37
• C and 5% CO 2 . Then the specimens were minced and digested in 0.25 % collagenase type IA (Gibco) at 37
• C in a shaking water bath for about 50 min. Two to three volumes of pre-warmed culture medium was used to stop the collagenase activity. The cell suspension was successively filtered through a 154-mm monofilament cupreous mesh and a 38.5-mm monofilament cupreous mesh. The filtrate containing stromal cells was collected and centrifuged at 1000 rpm/min for 5 min; the pellet was resuspended.
To remove the nonattached cells, the culture medium was replaced with fresh medium 2 h later. The 38.5-mm monofilament cupreous mesh was washed thoroughly upside down with culture medium, then the cell suspension containing glandular epithelial cells was collected and centrifuged at 1000 rpm/min for 5 min; the pellet was resuspended.
Expressive plasmids and small interfering RNAs pEGFP-C1 or pEGFP-C1-PDCD4 plasmids were kindly provided by Dr Olubunmi Afonja (New York University, New York, NY, USA). Two different Silencer Select Predesigned small interfering RNA (siRNA) targeting PDCD4 (siPDCD4) and nonspecific negative control (siControl) were synthesized from Genepharma (Shanghai, China). For siPDCD4-1: 5 GAGAUGGAAUUUUAUGUAAtt3 and 5 UUACAUAAAAUUCCAUCUCca; for siPDCD4-2: 5 GGCUGGAAUAAUUUCCAAAtt3 and 5 UUUGGAAAUUAU UCCAGCCtg. Negative control: 5 UUCUCCGAACGUGUCACG UTT-3 and 5 -ACGUGACACGUUCGGAGAATT-3 . Transfection of expressive plasmids and siRNAs was performed using Lipofectamine 2000 according to the manufacturer's protocols (Invitrogen Corp., Carlsbad, CA, USA). Then RT-PCR and western blot were used to confirm the transfection efficiency. 
RNA isolation and RT-PCR
Cell proliferation assay
The PDCD4 overexpressed or silenced cells were seeded at a density of 3000 cells per well in 96-well plates and incubated at 37
• C for 0, 24, 48, and 72 h. Before the end of the culture, 10 μl of CCK-8 (Dojindo, Tokyo, Japan) was added for additional 1 h of incubation. The absorbance was measured at 450 nm to calculate the number of viable cells in each well. Each sample was performed in sextuplicate.
Colony formation assay
The PDCD4 overexpressed or silenced cells were seeded in 6-well plates at a density of 1000 cells per well and cultured at 37
• C for 10 days. At the end of the incubation, the cells were fixed with methanol and stained with 0.1% (w/v) crystal violet. The number of colonies with ≥50 cells was counted using Image-Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD, USA). The colonyforming efficiency was calculated (Percentage of colonies = Number of colonies formed/Number of cells inoculated × 100%). Each sample was performed in triplicate.
Cell cycle assay
The PDCD4 overexpressed or silenced cells were seeded in 6-well plates at a density of 4 × 10 5 cells per well and cultured at 37 FC500 (Beckman Coulter, Fullerton, CA, USA). The experiment was repeated three times.
Cell apoptosis assay
Annexin V-APC/7AAD apoptosis Kit (Multi sciences) was used to detect the effect of PDCD4 on apoptosis of endometrial cells. The dark. Finally, the stained cells were diluted to 500 μl with binding buffer and analyzed with flow cytometry using the Beckman Coulter Cytomics FC500 (Beckman Coulter). The experiment was repeated three times.
Transwell migration assay
The PDCD4 overexpressed or silenced cells were cultured for 24 h at 37
• C. Then the cells (5 × 10 5 /well) were suspended in serum-free medium and seeded into the upper chamber of a transwell apparatus with an 8 μm pore size membrane (Millipore, Bedford, USA). The lower compartments were filled with 750 μl medium containing 10% FBS. After 24 h of incubation, the cells that migrated to the bottom surface of the membrane were fixed with 100% methanol and stained with 0.5% crystal violet, followed by microscopy observation. The extent of migration was determined by counting the average number of migrated cells in five microscopic fields. All the assays were repeated three times.
Matrigel invasion assay
BD Biocoat Matrigel invasion chambers, control inserts, and wells (BD Biosciences, Bedford, MA) were used to evaluate the effect of PDCD4 on invasion ability of endometrial cells. Six hundred fifty microliters medium containing 10% FBS was added to each well of the 24-well plate followed immediately by the addition of 1 × 10 4 cells in 150 μl serum-free medium to each chamber and control insert. Plates were incubated for 24 h at 37
• C. Noninvading cells were removed from the upper surface of the membrane. The cells on the lower surface of membrane were fixed with 100% methanol and stained with 0.1% (w/v) crystal violet, and then examined by microscopy. Values for invasion were expressed as the average number of invasive cells in five microscopic fields. All the assays were repeated at least twice.
Immunocytochemistry
The primary endometrial glandular epithelial cells and stromal cells were cultured in 24-well plates with cover slips overnight, and then the cells on the cover slip were fixed in 4% paraformaldehyde and blocked with 10% goat serum. Next, the cells were incubated with mouse anti-Vimentin monoclonal antibody or mouse anti-Cytokeratin 7 (CK7) monoclonal antibody (ZSGB-Bio, Beijing, China) overnight at 4 • C, followed by HRP-conjugated goat antirabbit IgG (Gene Tech) for 1 h at 37
• C. The expression of Vimentin and CK7 was visualized using DAB (Gene Tech), and the nuclei were counterstained with hematoxylin. Each sample was performed in duplicate.
Statistical analysis
Statistical analysis was performed with Graph Pad prism 6 software (La Jolla, CA, USA). All data were reported as mean ± SEM. The chi-square test and Student t-test were performed to evaluate the statistical significance between two groups. P < 0.05 was considered statistically significant.
Results
PDCD4 expression was downregulated in the eutopic and ectopic endometrium of endometriosis patients
To explore the roles of PDCD4 in EM, we first detected the expression of PDCD4 mRNA and protein in the eutopic endometrium of EM patients and control endometrium by qRT-PCR and western blot. The results showed that PDCD4 mRNA and protein levels in the eutopic endometrium of EM patients were significantly lower than those in control endometrium (Figure 1 A and B) . Next, we further detected the expression of PDCD4 protein in eutopic or ectopic endometrium of EM patients and control endometrium by IHC. As shown in Figure 1C -I, II, III, IV, and V, PDCD4 protein was mainly located in the cytoplasm of glandular epithelial cells, while no obvious positive staining could be observed in endometrial stromal cells.
PDCD4 protein levels in the eutopic and ectopic endometrium of EM patients were obviously downregulated compared with control endometrium ( Figure 1D ). In addition, the staining index of PDCD4 in the proliferative phase was significantly higher than that in the secretory phase of control endometrium ( Figure 1E ) and the proliferative phase of eutopic endometrium ( Figure 1E ), as well as ectopic endometrium ( Figure 1E ).
PDCD4 suppressed the proliferation and colony-forming ability of endometrial cells
To explore the effect of PDCD4 on the proliferation and colonyforming ability of endometrial cells, we first detected the expression of PDCD4 in two endometrial cells (HEC-1-A and Ishikawa) using RT-PCR and western blot. As shown in Figure 2A Figure 3E and F). In contrast, the living cell number, colony number, and size were obviously increased in Ishikawa cells transfected siPDCD4-1 or siPDCD4-2 compared with the control cells ( Figure 3C , D, and G). Therefore, these data demonstrate that PDCD4 could inhibit the proliferation and colony formation ability of endometrial cells.
PDCD4 had no effects on cell cycle and apoptosis
In order to investigate the mechanism by which PDCD4 inhibited the cell viability and growth, we determined the effect of PDCD4 on the cell cycle and apoptosis using HEC-1-A cells transfected PDCD4 plasmid and Ishikawa cells transfected siPDCD4-1 or siPDCD4-2. The results revealed that PDCD4 overexpression and knockdown had no significant effects on the cell cycle ( Figure 4A and B) and apoptosis of endometrial cells ( Figure 4C and D).
PDCD4 inhibited autophagy in endometrial cells
In order to further determine the mechanism by which PDCD4 inhibited the proliferation of endometrial cells, we detected the expression of autophagy-related marker LC3B after PDCD4 overexpression or knockdown by western blot. Then, we found that PDCD4 overexpression significantly decreased the levels of LC3B-II. In contrast, the silence of PDCD4 increased the expression of LC3B-II ( Figure 4E and F). chambers compared with the control groups ( Figure 5A and C) . Inversely, PDCD4 knockdown in Ishikawa cells increased the number of cells migrating into the lower surface of the transwell membrane ( Figure 5E ). We also performed matrigel invasion assay using Ishikawa cells and HEC-1-A cells. As shown in Figure 5B and D, the number of cells passing through the chambers in the PDCD4 plasmid-transfected groups was significantly smaller than that in the control groups, while PDCD4 knockdown increased the number of cells invading into the lower surface of the transwell membrane ( Figure 5F ). These data indicate that PDCD4 could repress migration and invasion of endometrial cells.
PDCD4 inhibited the migration and invasion of endometrial cells by NF-κB/MMP2/MMP9 signal pathway
NF-κB/MMP2/MMP9 signal pathway plays important roles in cell migration and invasion. In order to elucidate the mechanism by which PDCD4 inhibited the migration and invasion of endometrial cells, we detected the expression of P65, p-P65, MMP2, and MMP9 after PDCD4 overexpression and knockdown. The results showed that the expression of p-P65, MMP2, and MMP9 was significantly downregulated after PDCD4 overexpression in HEC-1-A cells ( Figure 6A ), while the levels of p-P65, MMP2, and MMP9 were increased in Ishikawa cells transfected with siPDCD4-1 or siPDCD4-2 ( Figure 6B ). It has been reported that PDCD4 inhibits NF-κB-dependent transcription in human glioblastoma cells by direct interaction with p65. Therefore, we speculate that PDCD4 reduces MMP2 and MMP9 expression by regulating NF-κB signaling. These above results imply that the inhibitory effect of PDCD4 on the migration and invasion may be mediated by NF-κB/MMP2/MMP9 signaling pathway in endometrial cells.
PDCD4 inhibited the proliferation and migration of primary endometrial cells
To further determine the effect of PDCD4 on the proliferation and migration of endometrial cells, primary endometrial cells including endometrial glandular epithelial cells and endometrial stromal cells were isolated from control endometrium. The results from immunocytochemistry showed that glandular epithelial cells expressed CK7 and stromal cells expressed Vimentin ( Figure 7A ). We also found that PDCD4 overexpression significantly suppressed cell growth and migration in primary endometrial cells ( Figure 7B and D) . However, PDCD4 knockdown accelerated the growth and migration of primary endometrial cells ( Figure 7C and E). In addition, PDCD4 overexpression significantly decreased the levels of p-P65, MMP2, and MMP9 ( Figure 8A ). In contrast, the silence of PDCD4 increased the expression of p-P65, MMP2, and MMP9 ( Figure 8B ).
DISCUSSION
About the etiology of EM, some accept the theory that retrograde menstruation causes EM; however, others speculate there is an inherent change in the endometrium that allows for the development of the disease. Previous studies reveal that several tumor-related genes such as phosphatase and tensin homolog deleted on chromosome ten (PTEN) [26] , human nucleoside diphosphate kinase A (NME1) [27] , chloride channel 3 (CIC-3) [28] , and CD82 [29] are involved in susceptibility to EM.
PDCD4 is a well-documented tumor suppressor that could inhibit neoplastic transformation, tumor cell proliferation, migration, and invasion [30] . It has been reported that PDCD4 is downregulated in various human cancers, and associated with tumor progression and prognosis. In the present study, we found that the expression of PDCD4 mRNA and protein was decreased in eutopic endometrium of EM patients compared with control endometrium, suggesting PDCD4 downregulation in eutopic endometrium of EM patients may be also involved in the development of EM. In addition, we found that PDCD4 expression was significantly decreased in the progesterone-predominated secretory phase of control endometrium compared with that in estrogen-predominated proliferative phase, which suggests that PDCD4 expression is hormonally regulated in the human endometrium. However, in eutopic endometrium of EM patients, there was no statistically significant difference in PDCD4 expression between the proliferative phase and the secretory phase. These results were similar with our previous report about adenomyosis patients [31] . We speculate that the loss of cyclic variation of PDCD4 expression in eutopic endometrium of EM or adenomyosis patients implies the presence of hormone resistance in these patients.
In women with EM, the eutopic endometrium has specific characteristics that favor tissue survival, adhesion, and growth outside the uterine cavity [32] . Here, we found that PDCD4 overexpression effectively inhibited the proliferation and colony formation of endometrial cells, while PDCD4 knockdown promoted the cell growth and colony-forming ability, suggesting PDCD4 could play important inhibitory roles in development of EM. PDCD4-mediated proliferation suppression may attribute to cell cycle transition obstacle and the elevation of cell apoptosis level [33] . It has been reported that PDCD4 inactivated PI3K/Akt signaling and its downstream cell cycle factors CCND1 and CDK4 to inhibit cell growth and cell cycle transition in NSCLC [34] . Overexpression of PDCD4 in glioblastomaderived cell lines leads to decreased proliferation, increased apoptosis, and decreased colony formation in soft agar [35] . Our previous study showed that overexpression of PDCD4 in ovarian cancer cells induced cell cycle arrest and apoptosis [36] . Therefore, we also further explored the effect of PDCD4 on cell cycle and apoptosis, and found that PDCD4 overexpression and knockdown had no effect on cell cycle and apoptosis of endometrial cells. Our results were consistent with the report of Yang et al. They also determined that overexpression of PDCD4 in colon carcinoma cell line RKO cells did not induce apoptosis or alter their cell cycle progression [37] . A possible explanation for the discrepancies is that the function of PDCD4 might be cell-type specific. Autophagy is a conserved catabolic process whereby cellular proteins and organelles are engulfed by autophagosomes, digested in lysosomes, and recycled to sustain cellular homeostasis [38] . In previous study, we found that PDCD4 inhibited autophagy in multiple cancer cells or murine xenograft model, and PDCD4-attenuated autophagy was required for inhibition of tumor cell growth [38] . These data provide a novel mechanism of tumor suppression, suggesting that loss or decrease of PDCD4 in tumor could lead to abnormal autophagy and rapid cell proliferation [38] . In this study, we found that PDCD4 overexpression significantly decreased the levels of LC3B-II. In contrast, the silence of PDCD4 increased the expression of LC3B-II. These results indicate that PDCD4 could suppress the proliferation of endometrial cells maybe by inhibiting autophagy.
It is well known that cell motility, invasion, and angiogenesis are critical to the pathogenesis and the malignant-like transformation of EM [39] . Previous studies have found that PDCD4 could suppress cell invasion and migration in some malignant cells by upregulating the expression of tissue inhibitors of metalloproteinase 2 (TIMP2) [40] , or downregulating the expression of urokinase receptor (u-PAR) [41] and mesenchymal markers (N-cadherin and fibronectin) [42] [43] [44] . Here, we also found that PDCD4 overexpression inhibited the migration and invasion of endometrial cells, while reduced PDCD4 expression resulted in increased migration and invasion ability.
Extracellular matrix (ECM) degradation is the critical step of cell invasion. The eutopic endometrium of EM patients can proliferate, invade, and develop on the surface of the peritoneum or ovary through ECM degradation and angiogenesis [7] . MMPs, a family of zinc-dependent endopeptidases, are responsible for degrading many kinds of ECM proteins and cell migration or invasion [45] . It has been reported that the eutopic and ectopic endometrium from EM patients may be more invasive and prone to peritoneal implantation because of greater MMP-9 and less TIMP-3 mRNA expression compared with the endometrium of women without EM [46] . The upregulation of MMP-9 via activation of osteopontin (OPN) induced by estrogen may correlate with the migration of endometrial epithelial cells in patients with EM [47] . In addition, calcium-activated neutral protease 7 (CAPN7) expression was markedly upregulated in the eutopic endometrium and endometrial stromal cells of women diagnosed with EM. CAPN7 promoted the migration and invasion of human endometrial stromal cell by regulating MMP2 activity [48] . Here, we also found that the expression of MMP2 and MMP9 was significantly downregulated after PDCD4 overexpression in HEC-1-A cells or primary endometrial cells, while the levels of MMP2 and MMP9 were increased in Ishikawa cells or primary endometrial cells transfected with siPDCD4-1 or siPDCD4-2. These results support the notion that PDCD4 could regulate the expression of MMP2/MMP9 in endometrial cells and may play an important role in the pathogenesis of EM.
NF-κB appears to be constitutively activated in endometriotic cells [49] . The nuclear expression of NF-κB p65 is increased in the eutopic endometrium of women with advanced-stage EM, which strongly suggests that NF-κB signaling plays a crucial role in the pathogenesis and/or pathophysiology of EM [50] . A number of genes that regulate cell proliferation, apoptosis, migration, invasion, or angiogenesis are identified to be NF-κB target genes, including cyclin D1, cyclin E, cellular inhibitor of apoptosis proteins-1 (CIAP-1), CIAP-2, MMP9, and VEGF, etc. [51] [52] [53] . In the study, we found that the expression of p-P65 was lower in PDCD4 overexpressed cells and higher in PDCD4 silenced cells. It has been reported that PDCD4 could inhibit the mRNA expression of invasion-related but not apoptosis-or cell proliferation-related NF-κB target genes in human glioblastoma cells by direct interaction with p65 [54] . These results suggest that PDCD4 inhibits migration and invasion of endometrial cells via the downregulation of NF-κB-dependent MMP2/MMP9 expression.
In conclusion, to our knowledge, this is the first report to identify the involvement of PDCD4 in EM. Our results confirm that PDCD4 is downregulated in eutopic and ectopic endometrium of EM patients, and PDCD4 effectively inhibits the proliferation, colony formation, migration, and invasion of endometrial cells. The mechanism may be related to cell autophagy and NF-κB/MMP2/MMP9 signal pathway. Our findings provide a novel approach to target the aberrant PDCD4 expression in EM.
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